Pharmaceutical

CHMP backs MSD’s KEYTRUDA approval for urothelial carcinoma

The EMA CHMP has recommended approving MSD’s KEYTRUDA regimen as a first-line treatment for urothelial carcinoma.

Jul 30, 2024 - 04:00
CHMP backs MSD’s KEYTRUDA approval for urothelial carcinoma
The EMA CHMP has recommended approving MSD’s KEYTRUDA regimen as a first-line treatment for urothelial carcinoma.
Read the original article

Tags:

Previous Article

Bristol Myers Squibb reports dip in net income for Q2 2024

Next Article

New AI model boosts early osteoporosis diagnosis for ageing populations

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

USPTO grants Notice of Allowance for Tenax Therapeutics’ oral levosimendan

USPTO grants Notice of Allowance for Tenax Therapeutics...

Jun 1, 2023

Pembrolizumab by Merck for Sezary Syndrome: Likelihood ...

Nov 16, 2023

CymaBay seeks FDA approval for primary biliary cholangitis therapy

CymaBay seeks FDA approval for primary biliary cholangi...

Dec 18, 2023